Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research
Hepatology International · 2024-12 · 18 (6) · 1740-1755
DOI: 10.1007/s12072-024-10731-0 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Hepatology International, online erschienen am 16.10.2024. Verfasst von Maito Suoh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Storr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, 176 Hawkesbury Rd, Westmead, NSW, 21…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council of Australia, Cancer Institute NSW, University of Sydney.
Abstract (Originalsprache)
Background
The international consensus to revise non-alcoholic fatty liver disease to metabolic (dysfunction)-associated fatty liver disease (MAFLD) in 2020 attracted significant attention. The impact of the MAFLD definition on the research community has not been objectively assessed. We conducted an analysis of systematically collected literature on MAFLD to understand its research impact.
Methods
From PubMed, Web of Science, and Scopus, the literature adopting MAFLD, written in English, and published from 2020 to 10 October 2023 was collected. The publication metrics, including publication counts, publishing journals, author countries, author keywords, and citation information, were analyzed to evaluate the research impact and key topics on MAFLD.
Results
1469 MAFLD-related papers were published in 434 journals with a steady increase in the number. The intense publishing and citations activity on MAFLD indicates the large impact of the redefinition. Topic assessment with keyword and citation analysis revealed a transition from the proposal and discussion of the redefinition to clinical characterization of MAFLD with a focus on metabolic dysfunction. Moreover, the diagnostic criteria for MAFLD showed better performance in predicting hepatic and extrahepatic outcomes compared to NAFLD. The publications were from 99 countries with evidence of strong regional and global collaboration. Multiple international societies and stakeholders have endorsed MAFLD for its utility in clinical practice, improving patient management and promoting multidisciplinary care, while alleviating stigma.
Conclusion
This survey provides a quantitative measure of the considerable international impact and contributions of the MAFLD definition towards liver research and as part of the spectrum of cardiometabolic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Storr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, 176 Hawkesbury Rd, Westmead, NSW, 2145, Australia.
- Storr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, 176 Hawkesbury Rd, Westmead, NSW, 2145, Australia. jacob.george@sydney.edu.au.
Förderung
- National Health and Medical Research Council of Australia
- Cancer Institute NSW
- University of Sydney
Zitieren
APA
Suoh, M., Esmaili, S., Eslam, M., & George, J. (2024). Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research. Hepatology International, 18(6), 1740-1755. https://doi.org/10.1007/s12072-024-10731-0
Vancouver
Suoh M, Esmaili S, Eslam M, George J. Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research. Hepatology International. 2024;18(6):1740-1755. doi:10.1007/s12072-024-10731-0
BibTeX
@article{Suoh2024,
author = {Suoh, Maito and Esmaili, Saeed and Eslam, Mohammed and George, Jacob},
title = {Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research},
journal = {Hepatology International},
year = {2024},
volume = {18},
number = {6},
pages = {1740--1755},
doi = {10.1007/s12072-024-10731-0}
}
EUVIMED